Diasorin in red on the Stock Exchange following the news relating to the investigations by the Pavia Public Prosecutor's Office into the CEO of the company, Carlo Rosa, and the top management of the IRCCS San Matteo Foundation.
to 12.55 the share lost 1,85% at 175 euro (Ftse Mib - 0,9%) after hitting an intraday low of 174,10. A setback that fits into a strongly positive period for the group's shares. Diasorin, precisely because of its core business (immunodiagnostics and molecular diagnostics), it was among the companies that best withstood the outbreaks of the pandemic of coronavirus, achieving the best performance ever among the stocks in the main list since the beginning of the year. Since January, the shares of the Piedmontese company have gained more than 50% of their value, rising from 115,8882 to over 175 euros, with a capitalization of 9,599 billion.
To push today's sales, as mentioned, is the news relating to the investigations by the Pavia prosecutor's office on the agreement signed in April between the San Matteo Polyclinic of Pavia and the diagnostic company concerning the development of serological and molecular tests for the diagnosis of Covid-19 infections. Among the suspects, in addition to the managing director of Diasorin, Carlo Rosa, also the general manager and scientific director of the IRCCS San Matteo di Pavia Foundation and the head of the Molecular Virology Laboratory of the same institute.
The crimes alleged by the investigators are disturbed freedom of the procedure for choosing the contractor and embezzlement the crimes alleged by the investigators.
According to the prosecution, Diasorin would have been favored over potential competitors "by transferring to it all the results of the research and experimentation activities carried out by the IRCCS San Matteo di Pavia Foundation, in the sector of serological tests for the diagnosis of Covid-19 infection". The agreement between the parties, reads the note from the Public Prosecutor's Office, "was stipulated without a tender, making it possible for the Piedmontese company to obtain an economic advantage".
Further investigations are underway to outline the economic and commercial relations existing between Diasorin, the Insubrico Institute for Life Research Foundation and the company Servire Srl, all operating at the Insubrias Biopark in Gerenzano. The investigation begins with a complaint from a competitor of Diasorin.
At the beginning of June, the Lombardy Regional Administrative Court had canceled the agreement between the Policlinico and Diasorin accepting the appeal presented by Technogenetics.
"I reiterate the correctness of the work of the San Matteo Polyclinic, as also clarified by the Council of State, and I have full confidence in the investigating judiciary", said the president of the Pavia IRCCS, Alexander Venturi at Adnkronos Salute. Venturi is among the suspects along with the rest of the Irccs leaders. “I think that every citizen in a state of law should feel protected and not threatened when the judiciary investigates. That's how it is for us. We have nothing to hide and we are available to clarify the matter”, assures Venturi.
